NICE recommends systematic NHS funding for Bridge to Life's VitaSmart hypothermic oxygenated perfusion system
Executive summary: NICE published recommendations urging the NHS to systematically fund Bridge to Life's VitaSmart hypothermic oxygenated perfusion system. The guidance could drive widespread adoption of the technology across the UK healthcare system, impacting procurement spending and improving organ transplantation outcomes.
Who is involved: NICE, NHS, Bridge to Life Ltd., VitaSmart technology, UK healthcare providers
Likely next: NHS trusts may initiate procurement evaluations for VitaSmart, Bridge to Life could secure commercial contracts with UK hospitals, NICE may assess additional perfusion technologies for similar guidance
The UK's National Institute for Health and Care Excellence (NICE) has issued guidance advising the National Health Service (NHS) to routinely fund Bridge to Life's VitaSmart system, a hypothermic oxygenated perfusion technology for organ preservation. This recommendation signals a potential shift toward broader adoption of advanced perfusion technologies within the UK's transplant pathway, which could affect procurement budgets and clinical outcomes. While the guidance is not mandatory, it carries substantial weight in NHS purchasing decisions and may influence future health technology assessments.
Timeline
- — Au Royaume-Uni, le NICE publie des recommandations préconisant le financement systématique par le NHS du système de perfusion hypothermique oxygénée VitaSmart™ de Bridge to Life (PR Newswire)
Analysis — what this means
Likely next events
- NHS trusts expected to begin procurement evaluations for VitaSmart within the next quarter
- Bridge to Life may announce pricing agreements with UK hospital trusts by Q1 2027
- NICE may review additional perfusion technologies later in 2027
Sectors affected
- Medical devices
- Organ preservation technology
- NHS procurement
- Healthcare technology
Regulatory implications
- NICE guidance informs NHS reimbursement policy for medical devices
Historical parallels
- NICE previously recommended routine funding for ex vivo lung perfusion (EVLP) systems in 2022
- NICE endorsed normothermic regional perfusion for cardiac donation in 2021
Key entities
Sources
Open the full interactive case file on Beyond →